<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977378</url>
  </required_header>
  <id_info>
    <org_study_id>DVS20130806</org_study_id>
    <nct_id>NCT01977378</nct_id>
  </id_info>
  <brief_title>A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder</brief_title>
  <official_title>A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, 10-week study to evaluate the efficacy and safety of Sustained-Release
      Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride in adult with
      major depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17)</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on the Clinical Global Impression Scale</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI)</measure>
    <time_frame>Baseline to Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Remission Based on the HAM-D17 at Week 10</measure>
    <time_frame>Baseline to Week 10</time_frame>
    <description>Remission was defined as a HAM-D17 score of less than or equal to 7.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sustained-Release Desvenlafaxine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50-100mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sustained-Release Venlafaxine Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75-225mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained-Release Desvenlafaxine Hydrochloride</intervention_name>
    <arm_group_label>Sustained-Release Desvenlafaxine Hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained-Release Venlafaxine Hydrochloride</intervention_name>
    <arm_group_label>Sustained-Release Venlafaxine Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of Major Depressive Disorder

          -  Aged from 18 years to 65 years

          -  A primary diagnosis of Major Depressive Disorder based on the criteria in the
             Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM- IV-TR),
             single or recurrent episode, without psychotic features

          -  Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of ≧ 20

          -  Clinical Global Impressions Scale-Severity (CGI-S) score of ≧4

        Exclusion Criteria:

          -  Known hypersensitivity to desvenlafaxine or venlafaxine

          -  Significant risk of suicide based on clinical judgment

          -  Women who were pregnant,breast-feeding,or planning to become pregnant during study

          -  Had a history of seizure disorder

          -  History or current evidence of gastrointestinal disease known to interfere with the
             absorption or excretion of drugs or a history of surgery known to interfere with the
             absorption or excretion of drugs

          -  Any unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic, or
             other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang Li, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Shanghai Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang Li, Professor</last_name>
    <phone>86-021-34773128</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing An Ding Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Shanghai Mental Health</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang Li, Professor</last_name>
      <phone>86-021-34773128</phone>
      <email>lhlh_5@163.com</email>
    </contact>
    <investigator>
      <last_name>Huafang Li, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

